---
title: "CareDx, Inc. (CDNA.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CDNA.US/overview.md"
symbol: "CDNA.US"
name: "CareDx, Inc."
parent: "https://longbridge.com/en/quote/CDNA.US.md"
datetime: "2026-04-08T02:52:16.289Z"
locales:
  - [en](https://longbridge.com/en/quote/CDNA.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CDNA.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CDNA.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/CDNA.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CDNA.US/overview.md)


# CareDx, Inc. (CDNA.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 8000 Marina Boulevard, Brisbane, California, United States |
| Website | [caredx.com](https://caredx.com) |

## Company Profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes.

## Key Executives

| Name | Title |
|------|-------|
| John Walter Hanna | President, CEO & Director |
| Michael D. Goldberg | Independent Chairman |
| Keith S. Kennedy | CFO & COO |
| Jeffrey A. Novack | General Counsel & Secretary |
| Jessica Meng | Chief Commercial Officer |
| Kashif Rathore | Chief Technology Officer |
| Christine M. Cournoyer | Independent Director |
| Arthur A. Torres | Independent Director |
| R. Bryan Riggsbee | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| BlackRock, Inc. | 9.08% | 2025-12-31 |
| The Vanguard Group, Inc. | 6.69% | 2025-12-31 |
| Baron Capital Group, Inc. | 6.16% | 2025-12-31 |
| State Street Global Advisors, Inc. | 5.35% | 2025-12-31 |
| Deerfield Management Company, L.P. Series C | 4.28% | 2025-12-31 |
| ARK Investment Management LLC | 4.17% | 2025-12-31 |
| Gagnon Securities, LLC | 3.47% | 2025-12-31 |
| Braidwell LP | 3.10% | 2025-12-31 |
| Nikko Asset Management Co., Ltd. | 2.82% | 2025-12-31 |
| Dimensional Fund Advisors LP | 2.56% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biotechnology | 379805000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "CareDx, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 359939000 | 94.77% |
| Rest of World | 19866000 | 5.23% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**